Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9394726 | 0.86 | LMNA (0.45) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL30311893 | 0.79 | LMNA (0.43) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL10623725 | 0.79 | LMNA (0.43) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL29687953 | 0.77 | LMNA (0.58) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL982910 | 0.77 | LMNA (0.58) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| Phenazine SCHEMBL5691639 | 0.76 | LMNA (0.85) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL28399164 | 0.76 | LMNA (0.56) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL6032927 | 0.75 | LMNA (0.59) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL18748071 | 0.75 | LMNA (0.54) | LMNACYP3A4KDM4ESMN1; SMN2MAPT | |
| SCHEMBL17422697 | 0.73 | CYP3A4 (0.54) | LMNACYP3A4KDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081965-A | Synthesis method and application of electrochemical promotion of indolobenzselenazepine ketone compound | — | 2026-05-26 | — | — | CN | disclosed |
| EP-2822943-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2018-10-03 | — | — | EP | disclosed |
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2099804-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| EP-2518073-B1 | Compounds for the treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8921355-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN R & D IRELAND (IE) | 2014-12-30 | — | — | US | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| US-4070467-A | Trans-octahydro-pyrido-indolo-benzazepine-3-alkanols, -alkanonitriles,-alkanoic acid and ester as tranquilizers | ENDO LABORATORIES, INC. (US) | 1978-01-24 | — | — | US | disclosed |
| US-4018930-A | ANALGESICS, SEDATIVES, TRANQUILIZERS | ENDO LABORATORIES, INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3989717-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3989717-A | ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1976-11-02 | — | — | US | disclosed |
| US-3959300-A | Novel indolobenzazepine derivatives, useful as tranquilizers | ENDO LABORATORIES, INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3959300-A | Novel indolobenzazepine derivatives, useful as tranquilizers | ENDO LABORATORIES, INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | LMNA 3938/4885CYP3A4 54/4885KDM4E 1448/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | LMNA 3453/4885CYP3A4 500/4885KDM4E 2251/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | LMNA 3453/4885CYP3A4 500/4885KDM4E 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.